Literature DB >> 14982656

A systematic review and economic evaluation of magnetic resonance cholangiopancreatography compared with diagnostic endoscopic retrograde cholangiopancreatography.

E Kaltenthaler1, Y Bravo Vergel, J Chilcott, S Thomas, T Blakeborough, S J Walters, H Bouchier.   

Abstract

OBJECTIVES: To compare the clinical and cost-effectiveness of magnetic resonance cholangiopancreatography (MRCP) with diagnostic endoscopic retrograde cholangiopancreatography (ERCP) for the investigation of biliary obstruction. DATA SOURCES: Electronic bibliographic databases, the reference lists of relevant articles and various health services research-related resources. REVIEW
METHODS: The data sources were searched and selected studies were assessed using quality criteria. In total, 28 prospective diagnostic studies were identified reporting several suspected conditions plus one of patient satisfaction. Analyses were then performed to establish sensitivities, specificities, likelihood ratios and confidence intervals. The relative cost-effectiveness of adopting MRCP scanning in the investigation of the biliary tree was undertaken using a probabilistic economic model.
RESULTS: The median sensitivity for choledocholithiasis (13 studies) was 93% and the median specificity 94%. The median likelihood ratio for a positive value was 15.75 and for a negative value 0.08. Reported sensitivities for malignancy were somewhat lower, ranging from 81 to 86%, and specificities ranged from 92 to 100%. There was some evidence that MRCP is an accurate diagnostic test in comparison to ERCP, although the quality of studies was moderate. Claustrophobia prevented at least some patients from having MRCP in ten of the 28 studies. The other 18 studies did not mention claustrophobia. The probability of avoiding unnecessary diagnostic ERCP is estimated at 30%. These patients could avoid the unnecessary risk of complications and death associated with diagnostic ERCP, and substantial cost saving would be gained. The overall expected cost saving associated with MRCP is GBP149; the overall expected gain in quality-adjusted life-year is estimated at 0.011.
CONCLUSIONS: There is some evidence that MRCP is an accurate investigation compared with diagnostic ERCP, although the values for malignancy compared with choledocholithiasis were somewhat lower. The quality of studies was moderate. The limited evidence on patient satisfaction showed that patients preferred MRCP to diagnostic ERCP. The estimated clinical and economic impacts of diagnostic MRCP versus diagnostic ERCP are very favourable. The baseline estimate is that MRCP may both reduce cost and result in improved quality of life outcomes compared with diagnostic ERCP. Further research is suggested to compare MRCP and diagnostic ERCP with final diagnosis and also with the full range of target conditions; to examine patient satisfaction and ways of reducing problems with claustrophobia; to look at protocols to help identify who could most benefit from MRCP or ERCP; to assess the relative need and urgency of patient access to magnetic resonance imaging services, and also to determine how demand would affect availability and potential cost savings.

Entities:  

Mesh:

Year:  2004        PMID: 14982656     DOI: 10.3310/hta8100

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN: 1366-5278            Impact factor:   4.014


  20 in total

1.  Peritoneal fluid bilirubin to serum bilirubin ratio for the diagnosis of bile leaks in orthotopic liver transplant recipients.

Authors:  Anthony T DeBenedet; James M Scheiman; Grace H Elta; B Joseph Elmunzer
Journal:  Dig Dis Sci       Date:  2013-06-29       Impact factor: 3.199

2.  Comparative performance of non-contrast MRI with HASTE vs. contrast-enhanced MRI/3D-MRCP for possible choledocholithiasis in hospitalized patients.

Authors:  Stella K Kang; Laura Heacock; Ankur M Doshi; Justin R Ream; Jeffrey Sun; James S Babb
Journal:  Abdom Radiol (NY)       Date:  2017-06

3.  Endoscopic retrograde cholangiopancreatography for suspected choledocholithiasis: From guidelines to clinical practice.

Authors:  Joana Magalhães; Bruno Rosa; José Cotter
Journal:  World J Gastrointest Endosc       Date:  2015-02-16

4.  Management of Suspected Choledocholithiasis: A Decision Analysis for Choosing the Optimal Imaging Modality.

Authors:  Amnon Sonnenberg; Brintha K Enestvedt; Gennadiy Bakis
Journal:  Dig Dis Sci       Date:  2015-09-23       Impact factor: 3.199

5.  Endoscopic Ultrasonograpy for Choledocholithiasis and Biliary Malignancy.

Authors:  Bhavani Moparty; Manoop S Bhutani
Journal:  Curr Treat Options Gastroenterol       Date:  2005-04

6.  Three-dimensional MR Cholangiopancreatography in a Breath Hold with Sparsity-based Reconstruction of Highly Undersampled Data.

Authors:  Hersh Chandarana; Ankur M Doshi; Alampady Shanbhogue; James S Babb; Mary T Bruno; Tiejun Zhao; Esther Raithel; Michael O Zenge; Guobin Li; Ricardo Otazo
Journal:  Radiology       Date:  2016-03-16       Impact factor: 11.105

Review 7.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Authors:  John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor
Journal:  Gastroenterology       Date:  2013-07-01       Impact factor: 22.682

8.  Primary Sclerosing Cholangitis: Current and Future Management Strategies.

Authors:  John E Eaton; Jayant A Talwalkar
Journal:  Curr Hepat Rep       Date:  2013-03-01

9.  Minimum intensity projections of the biliary system using 16-channel multidetector computed tomography in patients with biliary obstruction: comparison with MRCP.

Authors:  Timm Denecke; Erika Degutyte; Lars Stelter; Lukas Lehmkuhl; Ray Valencia; Enrique Lopez-Hänninen; Roland Felix; Christian Stroszczynski
Journal:  Eur Radiol       Date:  2006-03-03       Impact factor: 5.315

10.  The added value of tomosynthesis in endoscopic retrograde cholangiography with radiography for the detection of choledocholithiasis.

Authors:  Yohsuke Suyama; Yoshitake Yamada; Hideki Yamaguchi; Gou Someya; Seiji Otsuka; Yoshitami Murayama; Hiroshi Shinmoto; Masahiro Jinzaki; Kenji Ogawa
Journal:  Br J Radiol       Date:  2018-04-16       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.